Verapamil attenuates intervertebral disc degeneration by suppressing ROS overproduction and pyroptosis via targeting the Nrf2/TXNIP/NLRP3 axis in four-week puncture-induced rat models both in vivo and in vitro.
Animals
Humans
Rats
Carrier Proteins
Cell Cycle Proteins
/ metabolism
Inflammasomes
/ metabolism
Intervertebral Disc
/ pathology
Intervertebral Disc Degeneration
/ drug therapy
NF-E2-Related Factor 2
/ metabolism
NLR Family, Pyrin Domain-Containing 3 Protein
/ metabolism
Punctures
Pyroptosis
Reactive Oxygen Species
/ metabolism
Verapamil
/ pharmacology
Intervertebral disc degeneration
Pyroptosis
ROS
TXNIP/Nrf2/NLRP3 axis
Verapamil
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
30
01
2023
revised:
22
07
2023
accepted:
09
08
2023
medline:
22
9
2023
pubmed:
15
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
Low back pain is usually caused by intervertebral disc degeneration (IVDD), during which the involvement of oxidation system imbalance and inflammasome activation cannot be neglected. In this study, we aimed to validate the expression level of TXNIP in IVDD and investigate the function and potential mechanism of action of verapamil. TXNIP is upregulated in the degenerate nucleus pulposus in both humans and rats, as well as in tert-butyl hydroperoxide (TBHP)-stimulated nucleus pulposus cells. Administration of verapamil, a classic clinical drug, mitigated the TBHP-induced overproduction of reactive oxygen species and activation of the NLRP3 inflammasome, thus protecting cells from pyroptosis, apoptosis, and extracellular matrix degradation. The Nrf2/TXNIP/NLRP3 axis plays a major role in verapamail-mediated protection. In vivo, a puncture-induced IVDD rat model was constructed, and we found that verapamil delayed the development of IVDD at both the imaging and histological levels. In summary, our results indicate the potential therapeutic effects and mechanisms of action of verapamil in the treatment of IVDD.
Identifiants
pubmed: 37579541
pii: S1567-5769(23)01114-1
doi: 10.1016/j.intimp.2023.110789
pii:
doi:
Substances chimiques
Carrier Proteins
0
Cell Cycle Proteins
0
Inflammasomes
0
NF-E2-Related Factor 2
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
Reactive Oxygen Species
0
TXNIP protein, human
0
TXNIP protein, rat
0
Verapamil
CJ0O37KU29
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110789Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.